Extract from CM(2021)131-addfinal

EUROPEAN COMMITTEE ON BLOOD TRANSFUSION (CD-P-TS)

Set up by the Committee of Ministers under Article 17 of the Statute of the Council of Europe and in accordance with Resolution CM/Res(2021)3 on intergovernmental committees and subordinate bodies, their terms of reference and working methods.

Type of committee: **Steering committee**
Terms of reference valid from: **1 January 2022 until 31 December 2025**[1]

PILLAR/PROGRAMME/SUB-PROGRAMME ▼

Pillar: Rule of Law
Programme: Action against crime, safety and security of citizens
Sub-programme: Quality of Medicines and Healthcare (EDQM, European Pharmacopoeia)

MAIN TASKS ▼

Under the authority of the Committee of Ministers, in its composition restricted to the representatives of the States Parties to the Convention on the Elaboration of a European Pharmacopoeia, the CD-P-TS will oversee and co-ordinate the Council of Europe's work in the field of blood transfusion and advise the Committee of Ministers on all questions within its field of competence. The overall aim is to ensure social rights by elaborating and promoting high ethical, safety and quality standards in the field of blood transfusion.

In particular, the CD-P-TS is instructed to:

(i) ensure the follow-up of the relevant decisions taken at the 131st Session of the Committee of Ministers (Hamburg, 21 May 2021),[2] and in particular contribute to the implementation of the key strategic priorities relating to its specific field of expertise as identified in the Strategic Framework of the Council of Europe, and respond to the respective key findings and challenges set out in the Secretary General's 2021 Report on the state of democracy, human rights and rule of law "A democratic renewal for Europe";

(ii) elaborate quality and safety standards in the collection, preparation, testing and use of blood and blood components based on the latest scientific developments; in particular, by updating and publishing, on a regular basis, the technical appendix to Committee of Ministers Recommendation R(95)15, also known as the Guide to the preparation, use and quality assurance of blood components, and promoting its implementation;

(iii) examine questions and monitor practices related to human blood transfusion, notably as regards quality and safety standards and their implementation, including collection, preparation, testing, storage, distribution and appropriate use of human blood and its components;

(iv) assist member States in improving and, if needed, in restructuring their blood transfusion services by promoting the principle of voluntary non remunerated donation;

(v) propose ethical, safety and quality standards for professional practices and blood component specifications;

(vi) ensure the transfer of knowledge and expertise and develop the competencies of experts through training and networking;

(vii) monitor practices in Europe and support the assessment of epidemiological risks and, in particular, the emergence of new blood-borne transmissible infectious agents that might jeopardise the safety of blood transfusion;

(viii) ensure availability of rare blood units by means of the European Database of Frozen Blood Units of Rare Groups;

(ix) draft proposals for recommendations and resolutions for adoption by the Committee of Ministers;

(x) support the organisation of external quality assessment programmes (EQA) such as proficiency testing schemes to measure the performance of testing laboratories in European blood establishments;

(xi) support the organisation of programmes helping European blood establishments in the implementation of harmonised quality management systems, and European regulatory and technical standards;

(xii) support the successful implementation of European Union (EU)/EDQM co-funded *ad hoc* activities aimed at implementing both EU and Council of Europe standards and harmonising practices in Europe;

(xiii) co-operate with the Steering Committee for Human Rights in the fields of Biomedicine and Health (CDBIO) in the implementation of all aspects of blood transfusion covered by the Convention on Human Rights and Biomedicine (ETS 164);

(xiv) take the pertinent aspects of the European Convention on Human Rights into consideration in its thematic work;

(xv) hold an exchange of views annually in order to evaluate its activities and advise the Committee of Ministers and the Secretary General on future priorities in its sector, including possible new activities and those that might be discontinued;

(xvi) take due account of the following mainstreamed perspectives in the performance of its tasks: gender, youth, children's rights, rights of persons with disabilities, and Roma and Traveller[3] issues;

---

[1] These terms of reference are approved for the first biennial period 2022-2023. For the second biennial period 2024-2025, they are approved on a provisional basis, subject to confirmation upon the adoption of the budget for 2024-2025.
[2] CM/Del/Dec(2021)131/2a, CM/Del/Dec(2021)131/2b, CM/Del/Dec(2021)131/2c and CM/Del/Dec(2021)131/3.
[3] The term "Roma and Travellers" is used at the Council of Europe to encompass the wide diversity of the groups covered by the work of the Council of Europe in this field: on the one hand a) Roma, Sinti/Manush, Calé, Kaale, Romanichals, Boyash/Rudari; b) Balkan Egyptians (Egyptians and Ashkali); c) Eastern groups (Dom, Lom and Abdal); and, on the other hand, groups such as Travellers, Yenish, and the populations designated under the administrative term "*Gens du voyage*", as well as persons who identify themselves as Gypsies. The present is an explanatory footnote, not a definition of Roma and/or Travellers.

(xvii) where relevant, contribute to building cohesive societies and to strengthening the role and meaningful participation of civil society in its work;

(xviii) in accordance with decisions CM/Del/Dec(2013)1168/10.2 of the Committee of Ministers, carry out, at regular intervals, within the limits of the available resources and bearing in mind its priorities, an examination of some or all of the conventions for which it has been given responsibility,[4] in co-operation, where appropriate, with the relevant convention-based bodies, and report back to the Committee of Ministers;

(xix) contribute to the achievement of, and review progress towards, the UN 2030 Agenda for Sustainable Development, in particular with regard to Goal 3: Good health and well-being and Goal 5: Gender equality.

MAIN DELIVERABLES ▼

Under the authority of the Committee of Ministers, the CD-P-TS is instructed to complete the following deliverables, within the following deadlines:

	Deadline ▼
1. Report on the Collection, Testing and Use of Blood and Blood Components in Europe (2017-2020)	31/12/2022
2. Guide to the preparation, use and quality assurance of blood components (21st edition), appendix to Recommendation Rec(95)15 on the preparation, use and quality assurance of blood components	31/12/2023
3. Guide to the preparation, use and quality assurance of blood components (22nd edition), appendix to Recommendation Rec(95)15 on the preparation, use and quality assurance of blood components	31/12/2025
4. Annual Report on the Collection, Testing and Use of Blood and Blood Components in Europe	31/12/2023 31/12/2024 31/12/2025

COMPOSITION ▼

MEMBERS:

Governments of the States Parties to the Convention on the Elaboration of a European Pharmacopoeia are invited to designate one representative of the highest possible rank with expertise in a field covered by these terms of reference. Each member of the committee shall have one vote. Where a government designates more than one member, only one of them is entitled to take part in voting.

The sending authorities of the member States will bear the travel and subsistence expenses for their representatives' participation in the meetings of the CD-P-TS. The travel and subsistence expenses of the Chair for participating in the meetings of the CD-P-TS-will be borne by the EDQM budget.

In accordance with decisions CM/Del/Dec(2013)1168/10.2 of the Committee of Ministers, in cases where there is no convention-based body including all the Parties, non-member States are invited to take part, with a right to vote, in the committee meetings pertaining to the conventions to which they are Parties.

PARTICIPANTS:

The following may send representatives, without the right to vote and at the charge of their corresponding administrative budgets:

- Parliamentary Assembly of the Council of Europe;
- Congress of Local and Regional Authorities of the Council of Europe;
- European Court of Human Rights;
- Council of Europe Commissioner for Human Rights;
- Conference of INGOs of the Council of Europe;
- Steering Committee for Human Rights in the fields of Biomedicine and Health (CDBIO);
- Committees or other bodies of the Council of Europe engaged in related work, as appropriate.

The following may send representatives, without the right to vote and without defrayal of expenses:

- Council of Europe member States other than those mentioned above under "Members" and other States with observer status to the European Pharmacopoeia Commission;
- European Union;
- Observer States to the Council of Europe: Canada, Holy See, Japan, Mexico, United States of America;
- World Health Organization (WHO).

OBSERVERS:

The following may send representatives, without the right to vote and without defrayal of expenses:

- Non-member States with which the Council of Europe has a Neighbourhood Partnership including relevant co-operation activities

Observer status may be requested in accordance with Article 8 of Resolution CM/Res(2021)3 on intergovernmental committees and subordinate bodies, their terms of reference and working methods.

[4] Cf. relevant decisions of the Committee of Ministers (CM/Del/Dec(2013)1168/10.2) and list of Conventions in document CM(2021)132.

WORKING METHODS ▼

	Plenary meetings ▼			Bureau meetings ▼		
	Members incl. Chair	Meetings per year	Days per meeting	Members	Meetings per year	Days per meeting
2022	39	1	2	8	1	2
2023	39	1	2	8	1	2
2024	39	1	2	8	1	2
2025	39	1	2	8	1	2

Extraordinary meetings of the CD-P-TS may be convened upon request by the Chair.

Representatives taking part in the committee and its subordinate bodies shall complete a declaration of interest and confidentiality undertaking form.

The rules of procedure of the committee are governed by Committee of Ministers Resolution CM/Res(2021)3 on intergovernmental committees and subordinate bodies, their terms of reference and working methods. However, with a view to reaching its objectives and to enable multidisciplinary working methods, the committee may in derogation of Resolution CM/Res(2021)3, within the limit of budgetary attributions, create subordinate bodies.

Subject to the agenda, the Chairs of its subordinate structures may be invited to attend CD-P-TS Bureau and/or plenary meetings.

The CD-P-TS will appoint from amongst its members up to 5 Rapporteurs on mainstreamed perspectives, including a Gender Equality Rapporteur.

BUDGETARY INFORMATION* ▼

	Meetings per year	Days Per meeting	Members reimbursed	Plenary in €K	Bureau in €K	Working groups in €K	Secretariat (A, B)
2022	1	2	1	8.0	0.8	-	1A, 1B
2023	1	2	1	8.0	0.8	-	1A, 1B
2024	*1*	*2*	*1*	*↔8*	↔	-	↔
2025	*1*	*2*	*1*	↔	↔	-	↔

* The costs include the per diem and travel costs of the Chair for participating in the meetings of the Committee and interpretation. They are calculated on the basis of the 2021 standard costs.